These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 22883694)

  • 1. The EMA perspective: case studies from the PDCO formulations group (chemicals & biologicals).
    Lebarbier C; Esteve I
    Int J Pharm; 2012 Oct; 435(2):131-2. PubMed ID: 22883694
    [No Abstract]   [Full Text] [Related]  

  • 2. The EMA quality guideline on the pharmaceutical development of medicines for paediatric use.
    van Riet-Nales DA; Wang S; Saint-Raymond A; Robert JL
    Int J Pharm; 2012 Oct; 435(2):132-4. PubMed ID: 22883695
    [No Abstract]   [Full Text] [Related]  

  • 3. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drugs for adults--and for the children?].
    Kalikstad B; Gramstad L
    Tidsskr Nor Laegeforen; 2005 Jun; 125(11):1470. PubMed ID: 15940308
    [No Abstract]   [Full Text] [Related]  

  • 5. European Union prepares to tackle counterfeit drugs.
    Watson R
    BMJ; 2010 May; 340():c2425. PubMed ID: 20442239
    [No Abstract]   [Full Text] [Related]  

  • 6. Developing a European framework for research on children's medicines: an examination of the proposed EU regulation on medicinal products for paediatric use.
    Seyberth HW; Demotes-Mainard J; Wrobel P
    Pediatr Nephrol; 2005 Nov; 20(11):1537-40. PubMed ID: 16167134
    [No Abstract]   [Full Text] [Related]  

  • 7. [New pharmaceutical legislation in Italy and Federal Republic of Germany in relation to European Economic Community directives].
    Cavatorta L
    Boll Chim Farm; 1979 Mar; 118(3):144-62. PubMed ID: 475906
    [No Abstract]   [Full Text] [Related]  

  • 8. [Import and export of drugs for own use].
    Bjerke M
    Tidsskr Nor Laegeforen; 2010 Jun; 130(12):1260-1. PubMed ID: 20567281
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory aspects of devices.
    Wachtel H
    Int J Pharm; 2012 Oct; 435(2):142-4. PubMed ID: 22883700
    [No Abstract]   [Full Text] [Related]  

  • 10. The drug-device interface.
    Cutler IR
    Med Device Technol; 1993 Jun; 4(5):48-51. PubMed ID: 10171678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of genotoxic impurities in pharmaceutical development.
    Bercu JP; Dobo KL; Gocke E; McGovern TJ
    Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patent watch: extra exclusivity for new medical uses.
    Harrison C
    Nat Rev Drug Discov; 2012 Sep; 11(9):666. PubMed ID: 22935795
    [No Abstract]   [Full Text] [Related]  

  • 14. Improving pharmacovigilance in Europe.
    Moore N; Bégaud B
    BMJ; 2010 Apr; 340():c1694. PubMed ID: 20385717
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of the pharmacopoeia in the control of pharmaceutical preparations.
    Grainger HS
    Ann Ist Super Sanita; 1975; 11(3-4):305-13. PubMed ID: 1234732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In the wake of the Mediator scandal: some progress in France, but apathy at the European level.
    Prescrire Int; 2012 Apr; 21(126):110. PubMed ID: 22515143
    [No Abstract]   [Full Text] [Related]  

  • 17. Maximizing exclusivity for drug products.
    French H
    Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
    [No Abstract]   [Full Text] [Related]  

  • 18. Counterfeiting and piracy of pharmaceuticals.
    Grackin A
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract]   [Full Text] [Related]  

  • 19. [Registration of veterinary drugs: order or chaos?].
    Sybesma W
    Tijdschr Diergeneeskd; 1993 May; 118(9):308-9. PubMed ID: 8488491
    [No Abstract]   [Full Text] [Related]  

  • 20. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.